nadofaragene firadenovec

Trials studying nadofaragene firadenovec

• phase3Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancerrecruitingn=454
• phase3A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancerrecruitingn=250
• phase2Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trialnot yet recruitingn=33
• phase2Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvisrecruitingn=20
• —ADSTILADRIN Early Utilization and Outcomes in the Real World Settingterminatedn=202
• phase4A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.withdrawn
• phase3ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)completedn=157